ProCE Banner Activity

BREAKWATER: Phase III Study of First-line Encorafenib + Cetuximab + Chemotherapy vs SoC for BRAF V600E–Mutant mCRC

Conference Coverage
Slideset

The phase III BREAKWATER study demonstrated statistically significant improvement in objective response rates and a manageable toxicity profile with first-line encorafenib plus cetuximab plus chemotherapy vs standard-of-care treatment in patients with BRAF V600E–mutant metastatic colorectal cancer.

Released: February 04, 2025

Expiration: August 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Exelixis, Inc., and Novartis Pharmaceuticals Corporation.

Boehringer Ingelheim Pharmaceuticals, Inc.

Exelixis, Inc.

Novartis Pharmaceuticals Corporation